Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs.The illumigene Mycoplasma test is currently in clinical trials, according to a statement from Meridian announcing the Cincinnati-area company’s first-quarter earnings. Meridian plans to launch three to four new illumigene tests per year, [...]

Diagnostic test maker Meridian Bioscience‘s (NYSE:VIVO) Chief Executive Jack Kraeutler received a 3 percent increase in compensation this year to $843,000.Here’s how Kraeutler’s 2011 compensation breaks down, according to a recent regulatory filing: $546,000 in base salary; $228,000 in stock awards and $69,000 in “other” compensation, which includes retirement contributions, auto allowance and financial planning.Unlike [...]

Meridian Bioscience Inc. (NASDAQ: VIVO), the Cincinnati, Ohio diagnostic test maker, has received FDA clearance for its new Clostridium difficile test.The ImmunoCard C. difficile GDH test has already been launched in global markets for screening of the bacteria, a common hospital-acquired infection. Toxigenic strains of C. difficile cause diarrhea and can lead to life-threatening complications [...]

Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received regulatory clearance of a molecular diagnostics test for group B streptococcus.The group B strep test is the second in the Cincinnati-area company’s illumigene line of molecular diagnostic tests to be cleared by the U.S. Food and Drug Administration. The illumigene product line is key to Meridian’s future [...]

Diagnostic testing company Meridian Bioscience (NASDAQ:VIVO) has filed a regulatory document that gives it the right to sell additional common and preferred shares.The document didn’t specify a dollar amount or number of shares the company could sell, or a date by which the company would make the sale.However, the document notes that Meridian is authorized [...]

Meridian Bioscience (NASDAQ:VIVO) plans to launch up to four new tests from its illumigene molecular diagnostic testing platform over the next year.Cincinnati-area Meridian is betting big on the illumigene platform, which it says provides its hospital and laboratory customers with a simpler, cheaper option to test samples for certain types of bacteria without the [...]

Market adoption of Meridian Bioscience’s (NASDAQ:VIVO) new molecular diagnostic testing platform illumigene will go a long way toward determining the company’s future.Cincinnati-area Meridian is betting big on the technology, hoping it’ll help rescue the diagnostic testing company from its recent struggles. The company has reported declining year-over-year earnings in several recent quarters and twice in [...]

More bad news for investors in diagnostic testing company Meridian Bioscience (NASDAQ:VIVO).The Cincinnati-area company now projects its full-year results to come in at the “lower end” of a range of 68 cents to 71 cents per share, according to a statement. The news comes after Meridian last month pushed its guidance down from its previous [...]

Diagnostics company Meridian Bioscience (NASDAQ:VIVO) plans to launch a new C. difficile test in Europe.C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. In recent years, C. difficile infections have become more frequent, more severe and more difficult to treat, [...]

Diagnostic testing company Meridian Bioscience (Nasdaq: VIVO) saw its shares fall as much as 13 percent in early trading Thursday, as the company downwardly revised its full-year earnings outlook.Shares of Meridian, whose tests can help doctors detect c. diff infection symptoms, were hovering around $23.87 in late-morning trading, after closing at $27.32 the prior day.In [...]